US FDA probes tumour risk tied to Novartis gene therapy

详细摘要

ZURICH: The US ​Food and Drug Administration said on Friday it was investigating a risk ‌of neoplasia, or tumour ​formation including malignancy, associated wit ...

The Swiss drugmaker Novartis earlier in the day disclosed two cases in which tumours in children showed evidence of being linked to its gene therapy drug

Novartis said that it had received ⁠nine reports overall of tumours in patients previously treated with Zolgensma since the therapy was first approved in 2019. The logo of Swiss drugmaker Novartis for illustrative purposes. (Reuters)

文章开头，摘自Emirates 24/7。如需阅读全文，请前往媒体网站。